Bulletin
Investor Alert

ACADIA Pharmaceuticals Inc.

NAS: ACAD

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 28, 2022, 5:00 p.m.

/zigman2/quotes/205236646/composite

$

22.11

Change

0.00 0.00%

Volume

Volume 205,204

Quotes are delayed by 20 min

/zigman2/quotes/205236646/composite

Previous close

$ 21.53

$ 22.11

Change

+0.58 +2.69%

Day low

Day high

$21.03

$22.13

Open

52 week low

52 week high

$15.68

$52.80

Open

Company Description

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations ...

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Valuation

Price to Sales Ratio

19.04

Price to Book Ratio

13.61

Enterprise Value to EBITDA

-12.47

Enterprise Value to Sales

6.07

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

735,033.00

Income Per Employee

-468,526.00

Receivables Turnover

10.02

Total Asset Turnover

0.56

Liquidity

Current Ratio

6.77

Quick Ratio

6.68

Cash Ratio

5.96

Profitability

Gross Margin

97.35

Operating Margin

-52.92

Pretax Margin

-63.60

Net Margin

-63.74

Return on Assets

-35.97

Return on Equity

-42.47

Return on Total Capital

-33.75

Return on Invested Capital

-40.90

Capital Structure

Total Debt to Total Equity

7.90

Total Debt to Total Capital

7.32

Total Debt to Total Assets

6.33

Long-Term Debt to Equity

7.09

Long-Term Debt to Total Capital

6.57

Officers and Executives

Name Age Officer Since Title
Mr. Stephen R. Davis 59 2014 Chief Executive Officer & Director
Dr. Srdjan R. Stankovic 63 2015 President
Mr. Brendan Teehan - 2018 Senior VP, Chief Insights & Analytics Officer
Mr. Mark Schneyer - 2020 Chief Business Officer & SVP-Business Development
Dr. Ponni Subbiah - 2019 Chief Medical Officer & Senior Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/06/2022 Stephen R. Davis
CEO; Director
3,718   Disposition at $23.05 per share. 85,699
01/06/2022 Srdjan R. Stankovic
President
1,937   Disposition at $23.05 per share. 44,647
01/06/2022 Austin D. Kim
EVP & General Counsel
574   Disposition at $23.05 per share. 13,230
01/06/2022 Brendan P. Teehan
EVP, COO, Head of Commercial
538   Disposition at $23.05 per share. 12,400
01/06/2022 Stephen R. Davis
CEO; Director
9,527   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2022 Srdjan R. Stankovic
President
5,444   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2022 Austin D. Kim
EVP & General Counsel
1,633   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2022 Brendan P. Teehan
EVP, COO, Head of Commercial
1,286   Derivative/Non-derivative trans. at $0 per share. 0
11/22/2021 Srdjan R. Stankovic
President
2,803   Disposition at $19.01 per share. 53,285
11/19/2021 Srdjan R. Stankovic
President
6,250   Derivative/Non-derivative trans. at $0 per share. 0
10/18/2021 Stephen R. Davis
CEO; Director
2,963   Disposition at $17.41 per share. 51,585
10/18/2021 Srdjan R. Stankovic
President
1,338   Disposition at $17.41 per share. 23,294
10/15/2021 Stephen R. Davis
CEO; Director
5,938   Derivative/Non-derivative trans. at $0 per share. 0
10/15/2021 Srdjan R. Stankovic
President
2,969   Derivative/Non-derivative trans. at $0 per share. 0
09/29/2021 Elizabeth A Garofalo
Director
1,918   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Baker Bros. Advisors LP
Director
12,782   Award at $0 per share. 0
06/22/2021 Baker Bros. Advisors LP
Director
12,782   Award at $0 per share. 0
04/30/2021 Stephen R. Davis
CEO; Director
7,850   Disposition at $20.33 per share. 159,590
04/30/2021 Srdjan R. Stankovic
President
4,230   Disposition at $20.33 per share. 85,995
04/30/2021 Austin D. Kim
EVP & General Counsel
1,054   Disposition at $20.33 per share. 21,427
04/30/2021 Elena H. Ridloff
EVP and CFO
1,032   Disposition at $20.33 per share. 20,980
04/29/2021 Stephen R. Davis
CEO; Director
15,625   Derivative/Non-derivative trans. at $0 per share. 0
04/29/2021 Srdjan R. Stankovic
President
9,615   Derivative/Non-derivative trans. at $0 per share. 0
04/29/2021 Austin D. Kim
EVP & General Counsel
3,005   Derivative/Non-derivative trans. at $0 per share. 0
04/29/2021 Elena H. Ridloff
EVP and CFO
3,245   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Stephen R. Davis
CEO; Director
14,195   Disposition at $50.61 per share. 718,408
02/04/2021 Srdjan R. Stankovic
President
8,429   Disposition at $50.61 per share. 426,591
02/04/2021 Austin D. Kim
EVP & General Counsel
2,107   Disposition at $50.61 per share. 106,635
02/04/2021 Elena H. Ridloff
EVP and CFO
2,051   Disposition at $50.61 per share. 103,801
02/04/2021 Stephen R. Davis
CEO; Director
31,250   Award at $0 per share. 0
02/04/2021 Srdjan R. Stankovic
President
19,231   Award at $0 per share. 0
02/04/2021 Austin D. Kim
EVP & General Counsel
6,009   Award at $0 per share. 0
02/04/2021 Elena H. Ridloff
EVP and CFO
6,490   Award at $0 per share. 0
/news/latest/company/us/acad

MarketWatch News on ACAD

  1. 5 Biotech Stocks That Could Lead a Revival

    1:05 p.m. Sept. 6, 2021

    - Barron's Online

  2. 5 Undervalued Healthcare Stocks

    10:54 a.m. June 16, 2021

    - Barron's Online

  3. Will Biotech Stocks' Slide Become a Rout? June Holds the Key.

    1:46 p.m. May 14, 2021

    - Barron's Online

  4. Acadia Pharmaceuticals stock price target cut to $26 from $40 at Canaccord Genuity

    8:10 a.m. April 6, 2021

    - Tomi Kilgore

  5. Acadia Pharmaceuticals downgraded to hold at Canaccord Genuity

    8:10 a.m. April 6, 2021

    - Tomi Kilgore

  6. Acadia Is Hit by Wave of Downgrades After FDA Rejection

    7:31 a.m. April 6, 2021

    - Barron's Online

  7. Acadia Pharmaceuticals stock price target cut to $25 from $37 at Mizuho

    5:42 a.m. April 6, 2021

    - Tomi Kilgore

  8. Acadia Pharmaceuticals downgraded to neutral from buy at Mizuho

    5:42 a.m. April 6, 2021

    - Tomi Kilgore

  9. The FDA Is Clamping Down. What to Know.

    6:16 a.m. March 29, 2021

    - Barron's Online

  10. Acadia Pharmaceuticals stock price target cut to $37 from $55 at Mizuho

    6:50 a.m. March 12, 2021

    - Tomi Kilgore

  11. Acadia Pharmaceuticals stock price target cut to $40 from $61 at Canaccord Genuity

    9:23 a.m. March 9, 2021

    - Tomi Kilgore

  12. Acadia Shares Plummet After FDA Finds Flaws in Drug Application

    8:18 a.m. March 9, 2021

    - Barron's Online

  13. Acadia Pharmaceuticals downgraded to outperform from strong buy at Raymond James

    7:45 a.m. March 9, 2021

    - Tomi Kilgore

  14. Acadia Pharmaceuticals stock price target cut to $42 from $60 at J.P. Morgan

    7:42 a.m. March 9, 2021

    - Tomi Kilgore

  15. Acadia Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus

    6:59 a.m. March 9, 2021

    - Tomi Kilgore

  16. Acadia Pharmaceuticals stock price target cut to $27 from $68 at Stifel Nicolaus

    6:59 a.m. March 9, 2021

    - Tomi Kilgore

  17. Loading more headlines...
/news/nonmarketwatch/company/us/acad

Other News on ACAD

  1. Tracking Baker Brothers Portfolio - Q3 2021 Update

    10:32 p.m. Jan. 4, 2022

    - Seeking Alpha

  2. JAGX, SEAC and EQOS among mid-day movers

    12:26 p.m. Dec. 21, 2021

    - Seeking Alpha

  3. Acadia Pharmaceuticals promotes Mark Schneyer to EVP CFO

    9:23 a.m. Dec. 14, 2021

    - Seeking Alpha

  4. Loading more headlines...

At a Glance

ACADIA Pharmaceuticals, Inc.

12830 El Camino Real

Suite 400

San Diego, California 92130-3331

Phone

1 8585582871

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$441.76M

Net Income

$-281.58M

2020 Sales Growth

30.3%

Employees

601.00

/news/pressrelease/company/us/acad

Press Releases on ACAD

  1. Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

    4:05 p.m. Nov. 8, 2021

    - BusinessWire - BZX

  2. Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

    8:00 a.m. Sept. 2, 2021

    - BusinessWire - BZX

  3. Acadia Pharmaceuticals Announces Executive Leadership Change

    3:05 p.m. Sept. 1, 2021

    - BusinessWire - BZX

  4. Parkinson Disease Therapeutics Market Outlook 2021-2027 By Industry Players

    10:28 p.m. Aug. 25, 2021

    - Market Insight Reports

  5. Loading more headlines...
Link to MarketWatch's Slice.